Real-world use of the second-generation cobalt-chromium sirolimus-eluting stents: 12-month results from the prospective multicentre FOCUS registry

Feng Zhang, Junbo Ge, Juying Qian, Lei Ge, Jun Zhou, Yuejin Yang, Fang Chen, Xiaoling Zhu, Shuzheng Lv, Zhizhong Li, Haichang Wang, Yin Liu, Yawei Xu, Zhanquan Li, Huigen Jin, Weiyi Fang, Xuchen Zhou, Lijun Jing, Yundai Chen, Changyong ZhouZhexun Lian, Yi An, Yongjian Yang, Zhixiong Zhong, Zuyi Yuan, Xiaofei Sun, Guotai Sheng, Zhenming Yan, Ren Ke Yi, Jian An, Bin Liu, Zesheng Xu, Xiaoqun Pu, Yongwen Qin, Shuangying Feng, Guosheng Fu, Chunlin Lai, Bo Yu, Tiemin Jiang, Lefeng Wang, Weiming Wang, Jianjun Peng, Hui Li, Wenyue Pang, Biao Xu, Haiming Shi, Meng Wei, Changqian Wang, Ying Zhu, Ningfu Wang, Shaoliang Chen, Qiang Fu, Shian Huang, Keng Wu, Yutian Tong, Zheng Zhang, Ge Zhang, Hesong Zeng, Hong Jiang, Wenwei Liu, Guoying Zhu, Ping Li, Xuekun Zhang, Zhimin Du, Yingfeng Liu, Weimin Li, Ling Liu, Ben He, Wei Gao, Dalin Jia, Jinchuan Yan, Shaorong Liu, Chuanhuan Zhang, Yimin Fang, Zhigang Tao, Jifu Li, He Huang, Xingui Guo, Xinghua Zhang, Tongbao Liu, Lianqun Cui, Jianming Xiao, Lianglong Chen, Jinfa Jiang, Chenzhi Lu, Xueqi Li, Peng Qu, Yan Wang, Honghua Ye, Jingtian Li, Yuqing Hou, Qiutang Zeng, Yuanze Jin, Dongju Jiang, Kanghua Ma, Dadong Zhang, Suwatchai Pornratanarangsi, Muhamad Munawar, Teguh Santoso

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Abstract

Aims: The FOCUS registry is a prospective, multicentre, web-based programme designed to collect clinical outcome data from real-world patients receiving the second-generation cobalt-chromium sirolimus-eluting stent (CoCr-SES). Methods and results: From March 2009 to February 2010, a total of 5,084 patients from 83 centres who were eligible to receive CoCr-SES were enrolled in the FOCUS registry. The primary endpoint was 12-month major adverse cardiac events (MACE, defined as the composite of cardiac death, myocardial infarction [MI], and target vessel revascularisation [TVR]). One-year data were available for 5,013 (98.6%) of the 5,084 patients enrolled. The primary endpoint occurred in 174 (3.47%) of 5,013 patients, consisting of 43 (0.86%) cardiac deaths, 132 (2.63%) MI, and 46 (0.92%) TVR. According to the Academic Research Consortium definition, definite and probable stent thrombosis (ST) occurred in 0.52% (26/5,013) of patients, including 19 cases of early ST and 7 of late ST. The 12-month MACE rates were 3.73% and 2.60% for extended-use and standard-use patients, respectively (p=0.065). Conclusions: The second-generation CoCr-SES was associated with low rates of 12-month MACE and ST in a broad spectrum of patients, thereby confirming the clinical safety and efficacy of this stent in a real-world setting.

Original languageEnglish
Pages (from-to)896-903
Number of pages8
JournalEuroIntervention
Volume8
Issue number8
DOIs
Publication statusPublished - Dec 2012

Keywords

  • Cobalt-chromium stent
  • Coronary artery disease
  • Sirolimus-eluting stent

Fingerprint

Dive into the research topics of 'Real-world use of the second-generation cobalt-chromium sirolimus-eluting stents: 12-month results from the prospective multicentre FOCUS registry'. Together they form a unique fingerprint.

Cite this